UK Companies House feature
AMPHASTAR UK LTD
Profile
- Company number
- 10140508
- Status
- Active
- Incorporation
- 2016-04-22
- Last accounts made up
- 2024-12-31
- Account category
- FULL
- Primary SIC
- 21100
- Hubs
- UK Healthcare
Accounts
Pending extraction
Audit & accounting basis
From AI-extracted PDF accounts
- Accounting basis
- FRS 101
- Reporting scope
- Standalone (parent only)
- Abridged
- Yes — abridged accounts (limited disclosure)
- Auditor
- Ernst & Young LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“The Company has received a support letter from its ultimate parent undertaking, Amphastar Pharmaceuticals, Inc. confirming that they will support the Company for a period of 12 months from the date of approving the 2024 financial statements. No material adverse changes in the trading performance or financial position of the Group or the Company are anticipated in the foreseeable future.”
Subsidiaries
- International Medication Systems (UK) Ltd. · 100% held · United Kingdom · Pharmaceuticals
Auditor / going-concern / subsidiary information is extracted from the PDF version of the latest annual accounts and is not tagged in iXBRL. About these numbers
People
6 active · 3 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| LIAWATIDEWI, Jacob | Secretary | 2016-05-23 | — | — |
| VISTRA COMPANY SECRETARIES LIMITED | Corporate Secretary | 2016-04-22 | — | — |
| LIAWATIDEWI, Jacob | Director | 2016-04-22 | Mar 1974 | American |
| LUO, Mary | Director | 2016-04-22 | Jul 1949 | American |
| PETERS, William | Director | 2016-04-22 | Aug 1967 | American |
| ZHANG, Jack | Director | 2016-04-22 | Sep 1946 | Chinese |
Show 3 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| LIAWATIDEWI, Jacob | Director | 2016-04-22 | 2016-04-22 |
| SHANDELL, Jason | Director | 2016-04-22 | 2016-04-22 |
| SHANDELL, Jason | Director | 2016-04-22 | 2020-04-10 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Amphastar Pharmaceuticals, Inc | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2016-04-22 | Active |
Filing timeline
Last 20 of 40 total filings
| Date | Type | Category | Description |
|---|---|---|---|
| 2026-03-31 | CH04 | officers | change corporate secretary company with change date |
| 2026-03-02 | AD01 | address | change registered office address company with date old address new address |
| 2025-09-15 | AA | accounts | accounts with accounts type full |
| 2025-04-23 | CS01 | confirmation-statement | confirmation statement with no updates |
| 2025-03-26 | PSC02 | persons-with-significant-control | notification of a person with significant control |
| 2025-03-26 | PSC09 | persons-with-significant-control | withdrawal of a person with significant control statement |
| 2024-10-28 | AA | accounts | accounts with accounts type full |
| 2024-04-24 | CS01 | confirmation-statement | confirmation statement with no updates |
| 2023-09-27 | AA | accounts | accounts with accounts type full |
| 2023-04-27 | CS01 | confirmation-statement | confirmation statement with no updates |
| 2022-09-29 | AA | accounts | accounts with accounts type full |
| 2022-04-22 | CS01 | confirmation-statement | confirmation statement with no updates |
| 2021-09-29 | AA | accounts | accounts with accounts type full |
| 2021-06-01 | CS01 | confirmation-statement | confirmation statement with no updates |
| 2020-12-01 | AA | accounts | accounts with accounts type full |
| 2020-04-28 | CS01 | confirmation-statement | confirmation statement with no updates |
| 2020-04-28 | TM01 | officers | termination director company with name termination date |
| 2019-09-24 | AA | accounts | accounts with accounts type full |
| 2019-04-23 | CS01 | confirmation-statement | confirmation statement with no updates |
| 2019-04-06 | CH04 | officers | change corporate secretary company with change date |
Credit score
Altman Z″ — composite of working capital, retained earnings, EBIT, and leverage
Activity Score
Filings velocity, capital events, officer churn, accounts trajectory